1. Pink Sheet

Neuroblastoma Drug Development: Potential Surrogate Endpoint Gets US FDA Panel Backing

 
• By Brenda Sandburg

Advisory committee supports further research on end-of-induction response as an early interim clinical endpoint for drugs in treatment of high-risk neuroblastoma. FDA has approved two drugs for this rare disease in children, who have a 40-50% chance of long-term survival.

Neuroblastoma
FDA advisory committee favors further research on potential surrogate endpoint for high-risk neuroblastoma • Source: Shutterstock

Given the lengthy time it takes to develop a drug for high-risk neuroblastoma, researchers are considering use of a surrogate marker for survival. A US Food and Drug Administration advisory panel agreed that end-of-induction response looks promising and that further research should be conducted to validate its use as an interim clinical endpoint.

The pediatric oncology subcommittee of FDA’s Oncologic Drugs Advisory Committee discussed the use of end-of-induction response in clinical trials for neuroblastoma treatments at its 12 May meeting. In a

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from US FDA Performance Tracker

More from Regulatory Trackers